Physician profile
Joel Garrison
NPI 1720426695
$3,807.83
in general payments reported to CMS, 2019-2025
25 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $219 · 2021: $467 · 2022: $703 · 2023: $1,036 · 2024: $695 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,014.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $537.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $471.35 | 2021-2025 | |
| Novo Nordisk INC | $452.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.66 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $286.87 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $194.45 | 2021-2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $194.40 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $185.55 | 2022-2024 | Rexulti |
| Glaxosmithkline, LLC. | $185.50 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $129.38 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $127.35 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.45 | 2020-2025 | Xifaxan |
| Dexcom, INC. | $98.89 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $83.26 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $76.31 | 2019-2023 | Spravato |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $70.53 | 2024 | |
| Pfizer INC. | $69.92 | 2019-2022 | |
| Aroa Biosurgery Incorporated | $56.67 | 2020 | |
| Mylan Specialty L.P. | $54.53 | 2021-2022 | |
| Integra Lifesciences Corporation | $31.87 | 2020 | |
| Astellas Pharma US INC | $28.92 | 2025 | Veozah |
| Genentech USA, INC. | $19.73 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.63 | 2024 | Voquezna |
| Nevro Corp. | $14.44 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.10 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.